Dongwha's Milikan, an anti-liver cancer drug, approved.

For the 3rd time of its history of domestic new drug development, Dongwha pharmaceutical company obtained the KFDA approval on July 6 over the new anti-liver cancer injectable drug, Milikan.

According to the KFDA, Dongwha has made about 4,300 million won of R&D investment from 1995 in a joint research cooperation with Korea Atomic Energy Research Institute by using a 166 isotope Holmium Ch...